Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 16/20 | 1.00 |
| ▸ | DRD2 | P14416 | 13/20 | 1.00 |
| ▸ | DRD3 | P35462 | 9/20 | 1.00 |
| ▸ | F3 | P13726 | 6/20 | 1.00 |
| ▸ | DRD5 | P21918 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.89 |
| ▸ | DRD4 | P21917 | 2/20 | 0.89 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.89 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.89 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | ACHE | P22303 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Corydalmine SCHEMBL12667453 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD3F3DRD5 | |
| Corydalmine SCHEMBL29243055 | 0.99 | DRD1 (0.98) | DRD1DRD2DRD3F3DRD5 | |
| Stepholidine SCHEMBL29943869 | 0.94 | DRD1 (1.00) | DRD1DRD2DRD3F3DRD5 | |
| Stepholidine SCHEMBL460434 | 0.94 | DRD1 (1.00) | DRD1DRD2DRD3F3DRD5 | |
| Stepholidine SCHEMBL10001966 | 0.94 | DRD1 (1.00) | DRD1DRD2DRD3F3DRD5 | |
| Stepholidine SCHEMBL10001965 | 0.94 | DRD1 (1.00) | DRD1DRD2DRD3F3DRD5 | |
| Stepholidine SCHEMBL29414100 | 0.94 | DRD1 (1.00) | DRD1DRD2DRD3F3DRD5 | |
| SCHEMBL26326556 | 0.92 | DRD1 (0.85) | DRD1DRD2DRD3F3DRD5 | |
| SCHEMBL22057260 | 0.91 | DRD1 (0.83) | DRD1DRD2DRD3F3DRD5 | |
| Demethylcorydalmine SCHEMBL12943247 | 0.89 | DRD1 (0.84) | DRD1DRD2DRD3F3DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112812112-B | Preparation method of isoquinoline alkaloid L-corydaline | 杨征 | 2024-06-28 | — | — | CN | disclosed |
| EP-3517537-B1 | DEUTERATED DERIVATIVE OF L-TETRAHYDROPALMATINE AND MEDICAL USE THEREOF | TAIZHOU HUAYUAN MEDICINAL TECH CO LTD (CN) | 2023-09-13 | — | — | EP | disclosed |
| EP-3517537-B1 | DEUTERATED DERIVATIVE OF L-TETRAHYDROPALMATINE AND MEDICAL USE THEREOF | TAIZHOU HUAYUAN MEDICINAL TECH CO LTD (CN) | 2023-09-13 | — | — | EP | disclosed |
| US-11236081-B2 | Crystalline salts of corydalmine | Yang, Zheng (CN) | 2022-02-01 | — | — | US | disclosed |
| US-20210347770-A1 | CRYSTALLINE SALTS OF CORYDALMINE | YANG, ZHENG (CN) | 2021-11-11 | — | — | US | disclosed |
| WO-2020107335-A1 | CRYSTALLINE SALTS OF CORYDALMINE | YANG ZHENG (CN) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020108330-A1 | CRYSTALLINE SALTS OF CORYDALMINE | YANG ZHENG (CN) | 2020-06-04 | — | — | WO | disclosed |
| US-10617679-B2 | Deuterated compounds and medical uses thereof | JINGLUWEIDAI INFORMATION CONSULTING SERVICE (BEIJING) CO. LTD. (CN) | 2020-04-14 | — | — | US | disclosed |
| US-10617679-B2 | Deuterated compounds and medical uses thereof | JINGLUWEIDAI INFORMATION CONSULTING SERVICE (BEIJING) CO. LTD. (CN) | 2020-04-14 | — | — | US | disclosed |
| US-20190240204-A1 | DEUTERATED COMPOUNDS AND MEDICAL USES THEREOF | TAIZHOU HUAYUAN MEDICINAL TECH CO. LTD. (CN) | 2019-08-08 | — | — | US | disclosed |
| US-20190240204-A1 | DEUTERATED COMPOUNDS AND MEDICAL USES THEREOF | TAIZHOU HUAYUAN MEDICINAL TECH CO. LTD. (CN) | 2019-08-08 | — | — | US | disclosed |
| EP-3517537-A1 | DEUTERATED DERIVATIVE OF L-TETRAHYDROPALMATINE AND MEDICAL USE THEREOF | Jingluweidai Information Consulting Service (Beijing) Co Ltd (CN) | 2019-07-31 | — | — | EP | disclosed |
| EP-3517537-A1 | DEUTERATED DERIVATIVE OF L-TETRAHYDROPALMATINE AND MEDICAL USE THEREOF | Jingluweidai Information Consulting Service (Beijing) Co Ltd (CN) | 2019-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10617679-B2 | Deuterated compounds and medical uses thereof | HRH4, HRH3, LPAR3 | DRD1 251/4885DRD2 213/4885DRD3 154/4885 |
| US-20190240204-A1 | DEUTERATED COMPOUNDS AND MEDICAL USES THEREOF | HRH4, HRH3, LPAR3 | DRD1 251/4885DRD2 213/4885DRD3 154/4885 |
| US-20210347770-A1 | CRYSTALLINE SALTS OF CORYDALMINE | NPC1L1, CHLSN, LIPA | DRD1 37/4885DRD2 50/4885DRD3 133/4885 |
| US-11236081-B2 | Crystalline salts of corydalmine | NPC1L1, CHLSN, LIPA | DRD1 37/4885DRD2 50/4885DRD3 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.